ENGLEWOOD, Colo., Nov. 2, 2020 /PRNewswire/ -- Ampio
Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company
focused on the advancement of immunology based therapies for
prevalent inflammatory conditions, announced today that the Company
will present a business and financial update webinar on
Thursday, November 5, 2020 at
4:30 pm EST.
Attending the conference call from Ampio will be Mr.
Michael Macaluso (President and
CEO), Dr. David Bar-Or (Director and Founder), Ms.
Laura Goldberg (Vice President) and
Mr. Daniel Stokely (CFO). The
business update portion of the call will consist of
a COVID-19 platform update from Dr. David Bar-Or and an update
on the OAK Trial from Laura
Goldberg. In addition to the business update,
Daniel Stokely, CFO, will present a
third quarter financial update.
To access the webinar, please log in to
https://www.webcaster4.com/Webcast/Page/2569/38512 approximately 10
minutes prior to the start of the call. To ask a question,
please dial in to 888-632-3385 (U.S.) or 785-424-1673
(International) and use the Participant Entry Code: 47668. Please
note that you can also ask a question through the webinar
platform.
A replay of this presentation will be available two hours after
the end of the call by dialing 877-481-4010 (U.S.) or 919-882-2331
(International). Replay Passcode: 38512
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion and its classification, as
well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application ("BLA"), the ability
of Ampio to enter into partnering arrangements,
clinical trials and decisions and changes in business
conditions and similar events, the ability to receive regulatory
approval to conduct clinical trials, that Ampion may be used to
treat ARDS induced by COVID-19, all of which are inherently subject
to various risks and uncertainties. The risks and uncertainties
involved include those detailed from time to time in Ampio's
filings with the Securities and Exchange Commission, including
without limitation, under Ampio's Annual Report on Form 10-K and
other documents filed with the Securities and Exchange Commission.
Ampio undertakes no obligation to revise or update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
Company Contact
Investor Relations
Joe Hassett
joeh@gregoryfca.com
484-686-6600
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-host-conference-call-on-november-5th-301164428.html
SOURCE Ampio Pharmaceuticals, Inc.